^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    QL1203

    i
    Other names: QL1203, QL-1203
    Company:
    Qilu Pharma
    Drug class:
    EGFR inhibitor
    Related drugs:
    over1year
    QL1203 In Combination With Chemotherapy for Metastatic Colorectal Cancer to Determine Efficacy and Safety (clinicaltrials.gov)
    P3, N=590, Recruiting, Qilu Pharmaceutical Co., Ltd. | Not yet recruiting --> Recruiting | Trial completion date: Mar 2023 --> Jul 2025 | Trial primary completion date: Oct 2022 --> Dec 2024
    Enrollment open • Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    5-fluorouracil • oxaliplatin • leucovorin calcium • QL1203
    over2years
    WX-0593 combined with an epithelial growth factor receptor (EGFR) monoclonal antibody in the treatment of xenograft tumors carrying triple EGFR mutations. (PubMed, Ann Transl Med)
    To evaluate the safety and therapeutic efficacy of WX-0593, a newly developed potent anaplastic lymphoma kinase (ALK) inhibitor, in combination with an epithelial growth factor receptor (EGFR) monoclonal antibody (QL1203 or Vectibix) for the treatment of xenograft tumors carrying mutant EGFR and osimertinib-resistant mutations (EGFR/T790M/C797S). WX-0593 exhibited a synergetic effect with an EGFR monoclonal antibody on osimertinib-resistant EGFR-mutant non-small cell lung cancer (NSCLC) both in vitro and in vivo. Their combination showed potent antitumor efficacy and an acceptable safety profile, which may be a promising strategy for the treatment of patients with EGFR triple-mutant NSCLC resistant to osimertinib.
    Journal
    |
    ALK (Anaplastic lymphoma kinase)
    |
    EGFR mutation • EGFR L858R • EGFR T790M • EGFR C797S • EGFR H1975
    |
    Tagrisso (osimertinib) • Vectibix (panitumumab) • Qi Xinke (iruplinalkib) • QL1203